Publication | Closed Access

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

UrologyGenitourinary CancerMedicineProstatic DiseaseOncologyRadiation OncologyProstate Cancer-specific MortalityBiochemical FailureTrog 96.01